The Lancet Oncology
Fecha de publicación: September 10, 2020
Autores: Prof Nicholas C Turner, MD , Belinda Kingston, MB, Lucy S Kilburn, MSc, Sarah Kernaghan, BSc, Prof Andrew M Wardley, MD, Iain R Macpherson, MD et al.
Background: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and the ability of ctDNA testing to select patients for mutation-directed therapy.Leer más